On March 29, Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) ( Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) ) disclosed the annual report for 2021. During the reporting period, the company realized an operating revenue of 281353 million yuan, an increase of 232.84% over 845304 million yuan in the same period of the previous year; The net profit was 598743 million yuan, turning losses into profits this year; Meanwhile, 369 million yuan of orders were added in 2021, including 221 million yuan of newly signed contracts for pharmaceutical R & D, a year-on-year increase of 194.67%; The newly signed contract for clinical research was 148 million yuan, with a year-on-year increase of 393.33%.
According to the data, Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) belongs to the pharmaceutical R & D service industry, which is mainly committed to the R & D and registration application of small molecule chemicals, the development of polypeptide drugs, the organization and implementation of phase I ~ IV clinical trials, bioequivalence trials, medical science services, R & D project consulting services, data management and statistical services, third-party testing (biological sample analysis, packaging material compatibility, base poison impurity analysis) and other drug R & D one-stop A comprehensive cro company providing whole process services and integrated solutions.
According to the company’s annual report, at present Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) is closely related to the development of the pharmaceutical R & D industry at home and abroad. With the development of China’s economy, the deepening of industrial reform, the aging population and the rise of medical expenses, as well as the continuous enhancement of public health awareness, it is expected that the scale of the pharmaceutical market will continue to grow. According to the relevant report, the scale of China’s cro market will be about 6.8 billion US dollars in 2019, China’s cro market is expected to reach US $22.2 billion in 2024, with a compound annual growth rate of about 26.5% from 2019 to 2024.
At the same time, the trend of pharmaceutical customized services has deepened, and the “patent cliff” has brought development opportunities for generic drugs and upstream pharmaceutical intermediates and API industries. According to the prediction of the report and relevant institutions, the total sales amount of drugs affected by patent expiration will reach 540 billion US dollars from 2010 to 2024. In order to speed up the listing progress of generic drugs and seize market share, it is also an inevitable choice for generic drug enterprises to cooperate with professional cro and CMO / cdmo service providers, which will bring development opportunities for the customized R & D and customized production of upstream intermediates and APIs
Statistics show that Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) main business covers early discovery and screening of new drugs, drug CMC development, clinical trials, registration and application, be / PK biological sample analysis and pharmaceutical testing services, clinical SMO and data services, MAH services, API and intermediate production and supply. It can provide customers with one-stop outsourcing and technical achievement transformation services from drug discovery, pharmaceutical CMC development, clinical trials and application and registration. It has more than 500 sops to fully ensure the compliance and efficiency of operation, and has 722 professional technical teams, including 90% of undergraduates and above, and 143 people with master’s degree and doctor’s degree or above. The company has two R & D buildings with an area of 30000 square meters. The company is equipped with perfect international advanced research instruments and equipment, and can carry out more than 100 pharmaceutical research projects at the same time.
Over the years, the company has provided R & D services to more than 200 pharmaceutical enterprises, including 50 of the top 100 Chinese pharmaceutical enterprises, and has successively completed more than 300 generic drug R & D applications. In the year, there were 15 new invention patent applications, 4 new Chinese patent authorizations, 1 U.S. patent authorization, 2 international patent applications, 2 patent challenges and 1 successful patent challenge; In total, there are 47 declared project specifications and 31 approved product specifications, of which 3 have been evaluated by the first imitation and 3 have been evaluated by the second company in total; Warwick pharmaceutical has successively been approved as a postdoctoral innovation practice base in Jiangsu Province and Nanjing city.
According to the disclosure of the annual report, Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) in the cro field, its advantages have been gradually reflected in the operation, specifically: the pharmaceutical R & D revenue is 1401373 million yuan, an increase of 546.62% over the previous year. In the annual report, the company said that the main reason is that the company strengthens the construction of the sales team and actively develops the market; Reduce the accounting unit, strengthen project process control and improve R & D efficiency; The income from clinical trials was 106705 million yuan, an increase of 215.46% over the previous year; The company said that the clinical trial not only expanded the clinical research business, but also actively developed the clinical business of innovative drugs and medical devices.
For future development, Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) said in the annual report that it will take the “pharmaceutical health” industry as the core business, take “adjusting structure, expanding scale and extending industrial chain” as the main line, and take “improving differentiated core competitiveness” as the goal, strengthen the optimization and upgrading of pharmaceutical R & D and clinical research business sectors, actively cultivate the “biomedicine” sector, and expand the upstream and downstream industrial chain through strategic mergers and acquisitions, Continue to improve the core technical capabilities of pharmaceutical research and development, clinical research, registration and application, and production and manufacturing of intermediates to characteristic APIs, and strive to become China’s leading pharmaceutical cro / C (d) Mo enterprise to better meet the diversified needs of patients and customers.
It is noteworthy that there are many leaders in the pharmaceutical industry in Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) management Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) director Huang Hui once served as the head of small molecule drug research and development of essotop branch of Changshu Huayi Chemical Co., Ltd Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) director and rotating general manager Jing Tao has more than ten years of rich experience in scientific research and entrepreneurship, operation management, market strategy, strategic consulting, investment and M & A in the field of life sciences Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) director and deputy general manager Xia Yan once led and was responsible for the phase II / III clinical research of more than 100 new drugs, involving many disciplines Xinjiang Bai Hua Cun Pharma Tech Co.Ltd(600721) two independent directors specializing in the pharmaceutical industry are leaders in China’s biomedical innovation and industry elites in the fields of high-throughput sequencing and epigenetics.
